Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > does the cannacord private placement was in cad or u.s ?

<< Previous

Bullboard Posts

Next >>

Comment by MrVerbatim9800on Dec 15, 2020 11:04am

245 Views

Post# 32108663

RE:does the cannacord private placement was in cad or u.s ?

CAD. The current share price (s) are simply an opportunityto buy in. This is going up (after a bit of tug and pull) in the next few days and into next week. Leverage up ;). MMED. Asks are very weak and the bids are high...